CA87025/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2003	1
2004	1
2005	1
2006	5
2007	2
2008	2
2009	4
2010	3
2011	7
2012	5
2013	4
2015	4
2024	0

1

T-cell-independent antitumor effects of CD40 ligation.

Rakhmilevich AL, Alderson KL, Sondel PM. Rakhmilevich AL, et al. Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337. Int Rev Immunol. 2012. PMID: 22804571 Free PMC article. Review.

2

NK cell-based immunotherapies in Pediatric Oncology.

McDowell KA, Hank JA, DeSantes KB, Capitini CM, Otto M, Sondel PM. McDowell KA, et al. J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93. doi: 10.1097/MPH.0000000000000303. J Pediatr Hematol Oncol. 2015. PMID: 25590232 Free PMC article. Review.

3

Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.

Goldberg JL, Sondel PM. Goldberg JL, et al. Semin Oncol. 2015 Aug;42(4):562-72. doi: 10.1053/j.seminoncol.2015.05.012. Epub 2015 Jun 3. Semin Oncol. 2015. PMID: 26320061 Free PMC article. Review.

4

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

Alderson KL, Sondel PM. Alderson KL, et al. J Biomed Biotechnol. 2011;2011:379123. doi: 10.1155/2011/379123. Epub 2011 May 24. J Biomed Biotechnol. 2011. PMID: 21660134 Free PMC article. Review.

5

Antibody-based immunotherapy in high-risk neuroblastoma.

Johnson E, Dean SM, Sondel PM. Johnson E, et al. Expert Rev Mol Med. 2007 Dec 17;9(34):1-21. doi: 10.1017/S1462399407000518. Expert Rev Mol Med. 2007. PMID: 18081947 Review.

6

Preclinical and clinical development of immunocytokines.

Sondel PM, Hank JA, Gan J, Neal Z, Albertini MR. Sondel PM, et al. Curr Opin Investig Drugs. 2003 Jun;4(6):696-700. Curr Opin Investig Drugs. 2003. PMID: 12901228 Review.

7

Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.

Shi Y, Felder MA, Sondel PM, Rakhmilevich AL. Shi Y, et al. Mol Immunol. 2015 Aug;66(2):208-15. doi: 10.1016/j.molimm.2015.03.008. Epub 2015 Mar 28. Mol Immunol. 2015. PMID: 25829245 Free PMC article.

8

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.

Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM. Albertini MR, et al. Cancer Immunol Immunother. 2012 Dec;61(12):2261-71. doi: 10.1007/s00262-012-1286-5. Epub 2012 Jun 8. Cancer Immunol Immunother. 2012. PMID: 22678096 Free PMC article. Clinical Trial.

9

Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL. Qu X, et al. Int Immunopharmacol. 2013 Dec;17(4):1141-7. doi: 10.1016/j.intimp.2013.10.019. Epub 2013 Nov 4. Int Immunopharmacol. 2013. PMID: 24201083 Free PMC article.

10

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL. Buhtoiarov IN, et al. Immunology. 2011 Feb;132(2):226-39. doi: 10.1111/j.1365-2567.2010.03357.x. Epub 2010 Oct 13. Immunology. 2011. PMID: 21039467 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

36 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year